Status:
UNKNOWN
ddcfDNA in Kidney Transplant Recipients
Lead Sponsor:
Seoul National University Hospital
Collaborating Sponsors:
Samsung Medical Center
Asan Medical Center
Conditions:
Kidney Transplant Rejection
Eligibility:
All Genders
18+ years
Brief Summary
The objective of this study is to predict subclinical Antibody-Mediated Rejection (ABMR) occurrences in de novo DSA-positive recipients maintaining stable renal function after transplantation. This wi...
Eligibility Criteria
Inclusion
- Recipients aged 18 and above
- Patients with de novo DSA positivity post-kidney transplantation and stable renal function: De novo HLA DSAs encompass both class I and class II, with Mean Fluorescence Intensity (MFI) greater than 1000. Stable renal function is defined as serum creatinine variation of less than 15% compared to the last 6 months.
- Patients with detected de novo HLA-DSAs but did not undergo histological examinations.
Exclusion
- Multi-organ transplant recipients
- Recipients with positive preformed DSAs
- ABO-incompatible transplant recipients
- Pediatric recipients under 18 years old at the time of transplantation
- Recipients lost to follow-up observation
- atients already subjected to histological examinations due to positive De novo HLA-DSAs.
Key Trial Info
Start Date :
December 26 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2025
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06013358
Start Date
December 26 2022
End Date
February 1 2025
Last Update
August 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea, 110-744